Emerging infectious diseases are those that have recently appeared in a population or have existed but are rapidly increasing in incidence, geographic range, or host range. These diseases often arise from a variety of factors, including climate change, globalization, urbanization, and the continuous interaction between humans, animals, and the environment. Examples range from newly identified viruses like SARS-CoV-2 (which causes COVID-19) to known pathogens, such as the influenza virus, that are constantly evolving. The unpredictable nature of these diseases makes them a major global health threat, requiring constant vigilance, rapid response, and a coordinated approach to surveillance, diagnosis, and treatment.
Market Analysis: The market for products and services related to emerging infectious diseases is experiencing significant growth, driven by the need for better preparedness and response to new outbreaks. In 2025, the global infectious disease diagnostics market is valued at approximately $26.58 billion, and the infectious disease therapeutics market is estimated at $72.5 billion. The diagnostics market is projected to reach around $42.20 billion by 2030, with a compound annual growth rate (CAGR) of 9.7%, while the therapeutics market is projected to grow to $101 billion by 2030, with a CAGR of 6.9%. The market's future growth is fueled by a rising number of zoonotic diseases, technological advancements in rapid diagnostics like Next-Generation Sequencing (NGS) and AI-based tools, and increased government funding for research and public health initiatives. While North America currently leads this market, the Asia-Pacific region is expected to show the fastest growth due to its large population, increasing investment in healthcare, and the high burden of infectious diseases.
